| Assessment Status | Assessment process complete |
| HTA ID | - |
| Drug | Trametinib |
| Brand | Mekinist® |
| Indication | For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. |
| Assessment Process | |
| Rapid review commissioned | 27/11/2015 |
| Rapid review completed | 22/12/2015 |
| Rapid review outcome | Full Pharmacoeconomic Assessment Recommended. |
| Full pharmacoeconomic assessment commissioned by HSE | 27/07/2016 |
| NCPE assessment completed | 15/03/2017 |
| NCPE assessment outcome | Reimbursement Not Recommended at the submitted price. |
The HSE has approved reimbursement following confidential price negotiations; April 2018.
